Prophylactic Tranexamic Acid To Reduce Blood Loss During Caesarean Delivery.

Condition(s) studied

Investigational drug(s) / intervention(s)

Tranexamic acid injection: All women recruited to Group A will receive tranexamic acid 1 gram in 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.

Placebo: All women recruited to Group B will receive 100 ml Normal Saline as intravenous infusion 10 minutes before the skin incision.

Study summary

Postpartum hemorrhage continues to be the leading cause of maternal morbidity and mortality. Globally, it is responsible for 25% of all pregnancy-related deaths. PPH is unpredictable and may occur in the absence of risk factors. Tranexamic acid is an antifibrinolytic proven to reduce blood loss and transfusion requirements for various surgeries. This study aims to explore the effectiveness of tranexamic acid as an adjunct to other uterotonics before the Caesarian Section.

Eligibility

Primary outcome measure(s)

• Perioperative blood loss — Amount of blood loss from starting from surgical incision till 24 hours post caesarean section.
  The primary aim of the trial is to investigate the effect of tranexamic acid on peri and post- operative blood loss during caesarean section

Trial sites (1)